Targeting memory loss with aspirin, a molecular mechanism perspective for future therapeutic approaches

被引:3
|
作者
Gholami, Masoumeh [1 ]
Sadegh, Mehdi [1 ]
Koroush-arami, Masoumeh [2 ]
Norouzi, Shaghayegh [3 ]
Arismani, Rasoul Jafari [4 ]
Asadi, Erfan [5 ]
Amini, Mohammad [5 ]
Khodayari, Nahid [1 ]
机构
[1] Arak Univ Med Sci, Fac Med, Dept Physiol, Arak 3848176941, Iran
[2] Iran Univ Med Sci, Sch Adv Technol Med, Dept Neurosci, Tehran, Iran
[3] Univ Kentucky Markey Canc Ctr, Lexington, KY USA
[4] Arak Univ Med Sci, Fac Med, Dept Surg, Arak, Iran
[5] Arak Univ Med Sci, Fac Med, Arak, Iran
关键词
Acetylsalicylic acid; Cyclooxygenase; Dementia; Alzheimer; Synaptic plasticity; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PASSIVE-AVOIDANCE TASK; SENSING ION CHANNELS; ALZHEIMERS-DISEASE; SYNAPTIC PLASTICITY; OXIDATIVE STRESS; PROSTAGLANDIN SYNTHESIS; CYCLOOXYGENASE-2; COX-2; PRIMARY PREVENTION; BRAIN;
D O I
10.1007/s10787-023-01347-1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Acetylsalicylic acid (ASA), also known as aspirin, was discovered in 1897 as an acetylated form of salicylate. It has been widely used for its anti-inflammatory and antiplatelet effects. It is commonly used for its cardiovascular benefits and is prescribed as secondary prophylaxis after a heart attack. Furthermore, low-dose, long-term ASA is used to reduce the risk of heart attack and stroke in individuals without prior cardiovascular disease. Acetylsalicylic acid acts as a non-selective inhibitor of cyclooxygenase (COX), which inhibits the synthesis of prostaglandins and prevents pro-inflammatory cytokines. Findings suggest that targeting cytokines and growth factors could be a potential therapeutic strategy for reducing neuroinflammation and slowing down the progression of dementia. Additionally, prostaglandins contribute to synaptic plasticity and can act as retrograde messengers in synapses. Research has implicated COX-1, one of the isoforms of the enzyme, in neuroinflammation and neurodegenerative disorders. The inhibition of COX-1 might potentially prevent impairments in working memory and reduce neuroinflammation caused by beta-amyloid proteins in some conditions, such as Alzheimer's disease (AD). Cyclooxygenase-2, an inducible form of the enzyme, is expressed in cortical and hippocampal neurons and is associated with long-term synaptic plasticity. The inhibition or knockout of COX-2 has been shown to decrease long-term potentiation, a process involved in memory formation. Studies have also demonstrated that the administration of COX-2 inhibitors impairs cognitive function and memory acquisition and recall in animal models. There remains a debate regarding the effects of aspirin on dementia and cognitive decline. Although some studies suggest a possible protective effect of non-steroidal anti-inflammatory drugs, including aspirin, against the development of AD, others have shown inconsistent evidence. This review provides an overview of the effects of ASA or its active metabolite salicylate on learning, memory, and synaptic plasticity.
引用
收藏
页码:2827 / 2842
页数:16
相关论文
共 50 条
  • [41] Novel treatment planning approaches to enhance the therapeutic ratio: targeting the molecular mechanisms of radiation therapy
    M. Protopapa
    V. Kouloulias
    A. Kougioumtzopoulou
    Z. Liakouli
    C. Papadimitriou
    A. Zygogianni
    Clinical and Translational Oncology, 2020, 22 : 447 - 456
  • [42] Molecular Pathways: Novel Approaches for Improved Therapeutic Targeting of Hedgehog Signaling in Cancer Stem Cells
    Justilien, Verline
    Fields, Alan P.
    CLINICAL CANCER RESEARCH, 2015, 21 (03) : 505 - 513
  • [43] Targeting the Key Signaling Pathways in Breast Cancer: From Molecular Mechanism to Therapeutic Interventions
    Singh, Deepika
    Sahoo, Ankit
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2024,
  • [44] Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response
    Y-H Lee
    A D Judge
    D Seo
    M Kitade
    L E Gómez-Quiroz
    T Ishikawa
    J B Andersen
    B-K Kim
    J U Marquardt
    C Raggi
    I Avital
    E A Conner
    I MacLachlan
    V M Factor
    S S Thorgeirsson
    Oncogene, 2011, 30 : 4175 - 4184
  • [45] Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response
    Lee, Y-H
    Judge, A. D.
    Seo, D.
    Kitade, M.
    Gomez-Quiroz, L. E.
    Ishikawa, T.
    Andersen, J. B.
    Kim, B-K
    Marquardt, J. U.
    Raggi, C.
    Avital, I.
    Conner, E. A.
    MacLachlan, I.
    Factor, V. M.
    Thorgeirsson, S. S.
    ONCOGENE, 2011, 30 (40) : 4175 - 4184
  • [46] Targeting purine metabolism-related enzymes for therapeutic intervention: A review from molecular mechanism to therapeutic breakthrough
    Wu, Di
    Yang, Shengqiang
    Yuan, Chenyang
    Zhang, Kejia
    Tan, Jiachen
    Guan, Kaifeng
    Zeng, Hong
    Huang, Chunjie
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 282
  • [47] The emerging landscape and future perspective of SCLC transformation: From molecular mechanisms to therapeutic strategies
    Zhang, Chenyue
    Wang, Kai
    Wang, Haiyong
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 207
  • [48] Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
    C A van der Weyden
    S A Pileri
    A L Feldman
    J Whisstock
    H M Prince
    Blood Cancer Journal, 2017, 7 : e603 - e603
  • [49] Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
    van der Weyden, C. A.
    Pileri, S. A.
    Feldman, A. L.
    Whisstock, J.
    Prince, H. M.
    BLOOD CANCER JOURNAL, 2017, 7 : e603 - e603
  • [50] Molecular Elucidation and Therapeutic Targeting for Combating COVID-19: Current Scenario and Future Prospective
    Suchita, Wamankar
    Tilotma, Sahu
    Saurabh, Shrivastava
    Abhishek, Kumar
    Sagar, Sahu
    Lokesh, Kumar
    CURRENT MOLECULAR MEDICINE, 2022, 22 (10) : 894 - 907